Quoin Pharmaceuticals Announces Recruitment of Three Additional Patients in Investigator Pediatric Netherton Syndrome Study and Provides Positive 9 month ‘Whole Body’ Data Update from Ongoing Study

Core Insights - Quoin Pharmaceuticals Ltd. has announced the recruitment of three additional pediatric patients for its investigator-led study on Netherton Syndrome (NS) and reported highly positive clinical data from the first pediatric patient after 9 months of treatment with QRX003 [1][3][4] Group 1: Clinical Data and Patient Outcomes - The first pediatric patient treated with QRX003 showed complete healing of the skin after 9 months, with the Investigator's Global Assessment (IGA) score improving from 4 (severe) to 0 (clear) [2][6] - The patient's pruritus score decreased from 5 at baseline to 0 at 9 months, indicating a complete absence of itching [2][6] - The patient has experienced zero nightly sleep disturbances and has not required previously necessary medications such as antibiotics, antivirals, antihistamines, and glucocorticoids during the treatment period [2][4] Group 2: Recruitment and Future Expectations - Three additional pediatric subjects have been recruited for the NS study, with two located in Austria and one in Ireland, all set to receive QRX003 for an initial period of twelve weeks [3][4] - The company anticipates that data from these new subjects will further support the positive clinical outcomes associated with QRX003 as a treatment for NS [3][4] Group 3: About Netherton Syndrome and QRX003 - Netherton Syndrome is a rare hereditary skin disorder caused by a mutation in the SPINK5 gene, leading to severe skin barrier defects and a predisposition to allergies and infections [5][6] - QRX003 is a topical lotion designed to restore skin barrier function by acting as a serine protease inhibitor, addressing the underlying issues caused by the absence of the LEKTI protein in patients [6][7]